Healthy persons versus pacients with diabetes mellitus type 2 - Choosen parameters in serum and subcutaneous abdominal adipose tissue;Zdravé osoby versus pacienti s diagnózou diabetes mellitus 2. typu - Vybrané parametry v séru a v subkutánní abdominální tukové tkáni

Vnitrni Lekarstvi

Volumn 53, Issue 1, 2007, Pages 9-17

  Ben Yahia, Rabha ^a   Lichnovska R ^a   Janusova L ^a   Kuzmina, G ^a   Karpisek M ^b,c   Kollar P ^c   Petrek J ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b BioVendor Laborato e Brno   (Czech Republic)

^c UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

Author keywords

A FABP; Adiponectin; Diabetes mellitus type 2; E FABP; PPAR ; Subcutaneous adipose tissue

Indexed keywords

ADIPONECTIN; C PEPTIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL SUBCUTANEOUS FAT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN EXPRESSION; SEX DIFFERENCE;

EID: 33947704111     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Svačina Š, Owen K. Obezita, diabetes 2. typu a jejich kvantitativní vztahy. Vnitř Lék 2002; 48: 500-506.
2. Krempler F, Breban D, Oberkofler H et al. Leptin, peroxisome proliferator-activated receptor-γ, and CCAAT/enhancer binding protein-γ mRNA expression in adipose tissue of humans and their relation to cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2000; 20: 443-449.
3. Sivitz WI, Wayson SM, Bayless ML et al. Leptin and body fat in type 2 diabetes and monodrug therapy. J Clin Endocrinol Metab 2003; 88: 1543-1553.
4. Zamboni M, Zoico E, Fantin F et al. Relation between leptin and the metabolic syndrome in elderly women. J Gerontol A Biol Sci Med Sci 2004; 59: 396-400.
5. Miyazaki Y, Mahankali A, Wajcberg E et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin En-docrinol Metab 2004; 89: 4312-4319.
6. Fischer RM, Thorbe A, Hamsten A et al. Fatty acid binding expression in different human adipose tissue depots in relation to rates of lipolysis and insulin concentration in obese individuals, Mol Cell Biochem 2002; 239: 95-100.
7. Boord JB, Maeda K, Makowski L et al. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation 2004; 110: 1492-1498.
8. Memon RA, Tecott LH, Nonogaki K et al. Up-regulation of peroxisome proliferator-activated receptors (PPAR-γ) and PPAR-γ messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-γ-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 2000; 141: 4021-4031.
9. Hřebíček J. PPAR: Úloha v homeostáze glukózy a lipidů, v inzulinové rezistenci a v ateroskleróze. Čs Fyziol 2004; 53: 4-14.
10. Peters JM, Lee SS, Li W et al. Growth adipose brain and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator- activated receptor β/δ. Mol Cell Biol 2000; 20: 5119-5128.
11. Spiegelman BM. PPARγ in monocytes: less pain, any gain? Cell 1998; 93: 153-155.
12. Kawaguchi K, Sugiyama T, Hibasami H et al. PPAR-γ, TNF-α messenger RNA levels and lipase activity in the pregnant and lactating rat. Life Sci 2003; 72: 1655-1663.
13. Auboeuf D, Rieusset J, Fajas L. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-γ in adipose tissue of obese and NIDDM patients. Diabetes 1997; 46: 1319-1327.
14. Mukherjee R, Jow L, Croston GE et al. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoform PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists. J Biol Cel 1997; 272: 8071-8076.
15. Vidal-Puig AJ, Considine RV, Jimenez-Linan M et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity weight loss and regulation by insulin and glucocorticoids. J. Clin Invest 1997; 99: 2416-2422.
16. Zierath JR, Frevert EU, Ryder JW et al. Evidence against a direct effect of leptin on glukose transport in skeletal Musile and adipocytes. Diabetes 1998; 47: 1-4.
17. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994; 30: 1147-1156.
18. Heitzel AV, Bemlohr DA. Regulation of adipocyte gene expression by polyunsaturated fatty acids. Mol Cell Biochem 1998; 188: 33-39.
19. Schoonjans K, Staels B, Grimaldi P et al. Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivates feeding and liver proliferation. Eur J Biochem 1993; 216: 615-622.
20. Martin G, Schoonjans K, Lefebvre AM et al. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA syntethase genes by PPARα and PPARγ activators. Biol Chem 1997; 272: 28210-28217.
21. Auwerx J, Schoonjans K, Fruchart JC et al. Transcriptional control of triglyceride metabolism; fibrates change the expression of LPL and apo C-111 genes by activating the nuclear receptor PPAR. Atherosclerosis 1996; 124: S29-S37.
22. Boyle PJ. What are the effects of peroxisome proliferators-activated receptor agonists on adiponectin, tumor necrosis factor-α, and other cytokines in insulin resistance? Clin Cardiol 2004; 27(Suppl 4): IV11-IV16.
23. Haluzík M, Gavrilova O, LeRoith D. Peroxisome proliferator- activated receptor-α deficiency does not alter insulin sensitivity in mice maintained on regular or high-fat diet: hyperinsulinemic-euglycemic clamp studies. Endokrinology 2004; 145: 1662-1667.
24. Matsuzava Y, Shimomura I, Kihara S et al. Importance of adipocytokines in obesity-related diseases. Hormon Res 2003; 60(Suppl 3): 56-59.
25. Shimada T, Kojima K, Yoshiura K et al. Characteristics of the peroxisome proliferators activated receptors gamma (PPARγ) ligand induced apoptosis in colon cancer cells. Gut 2002; 50: 658-664.
26. Coppola G, Corrado E, Muratori I et al. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol 2006; 106: 16-20.
27. Xu A, Wang Y, Xu JY et al. A dipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006; 52: 405-413.
28. Gultekin T, Akin G, Ozer BK. Gender differences in fat patterning in children living in Ankara. Anthropol Anz 2005; 63: 427-437.
29. Machann J, Thamer C, Schnoedt B et al. Standardized assessment of whole body adipose tissue topography by MRI. J Magn Reson Imaging 2005; 21: 455-462.
30. Bonora E, Del Prato S, Bonadonna RC et al. Total body fat content and fat topography are associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women. Diabetes 1992; 41: 1151-1599.
31. Pietilainen KH, Kannisto K, Korsheninnikova E et al. Acquired obesity increases CD68 and TNF-α and decreases adiponectin gene expression in adipose tissue. A study in monozygotic twins. J Clin Endocrinol Metab 2006; přijato do tisku.
32. Koshiba K, Nomura M, Nakaya Y et al. Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis Med Invest 2006; 53: 87-94.
33. Smith JD, Al-Amri M, Sniderman AD et al. Leptin and adiponectin in relation to bo dy fat percentage, waist to hip ratio and the apoB/apoA1 ratio in Asian Indian and Caucasian men and women. Nutr Metab (London) 2006 (přijato do tisku).
34. Lacquemant C, Vasseur F, Lepretre F et al. Adipocytokins, obesity and development of type 2 diabetes. Med Sci (Paris) 2005; Spec No 10-18.
35. Kim SH, Abbasi F, Chu JW et al. Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. Diabetes 2005; 54: 2447-2452.
36. Carmina E, Orio F, Palomba S et al. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 2006; 119: 356.
37. Hojlund K, Frystyk J, Levin K et al. Reduced plasma adiponectin concentration may contribute to impaired insulin activation of glycogen synthase in skeletal muscle of patients with type 2 diabetes. Diabetologia 2006; přijato do tisku.
38. Sun X, Han R, Wang Z et al. Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Diabetologia 2006; přijato do tisku.